Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2

Name: Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2
License: Public Domain

Prof. Dr. Clemens Schmitt

ClinicalTrials.gov · Datasets · License: Public Domain

diffuse large b cell lymphoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 329505
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.